These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
754 related articles for article (PubMed ID: 35784321)
1. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P Front Immunol; 2022; 13():909910. PubMed ID: 35784321 [TBL] [Abstract][Full Text] [Related]
2. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers. Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824 [TBL] [Abstract][Full Text] [Related]
3. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
4. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426 [TBL] [Abstract][Full Text] [Related]
5. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting. Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634 [TBL] [Abstract][Full Text] [Related]
6. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220 [TBL] [Abstract][Full Text] [Related]
7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
8. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination. Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination. Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095 [TBL] [Abstract][Full Text] [Related]
10. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467 [TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186 [TBL] [Abstract][Full Text] [Related]
13. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069 [TBL] [Abstract][Full Text] [Related]
14. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up. Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903 [TBL] [Abstract][Full Text] [Related]
15. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162 [TBL] [Abstract][Full Text] [Related]
16. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766 [TBL] [Abstract][Full Text] [Related]
17. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
18. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]